Merck KGaA (MKGAF)
162.95
+7.50
(+4.82%)
USD |
OTCM |
Oct 06, 16:00
Merck Enterprise Value : 82.81B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 82.81B |
| October 05, 2026 | 79.55B |
| October 02, 2026 | 79.89B |
| October 01, 2026 | 77.05B |
| September 30, 2026 | 83.23B |
| September 29, 2026 | 83.24B |
| September 28, 2026 | 81.31B |
| September 25, 2026 | 81.29B |
| September 24, 2026 | 79.40B |
| September 23, 2026 | 77.44B |
| September 22, 2026 | 77.16B |
| September 21, 2026 | 78.79B |
| September 18, 2026 | 77.93B |
| September 17, 2026 | 77.32B |
| September 16, 2026 | 80.24B |
| September 15, 2026 | 78.01B |
| September 14, 2026 | 80.38B |
| September 11, 2026 | 79.01B |
| September 10, 2026 | 78.03B |
| September 09, 2026 | 80.31B |
| September 08, 2026 | 79.36B |
| September 04, 2026 | 81.14B |
| September 03, 2026 | 84.40B |
| September 02, 2026 | 83.14B |
| September 01, 2026 | 85.18B |
| Date | Value |
|---|---|
| August 31, 2026 | 82.40B |
| August 28, 2026 | 83.32B |
| August 27, 2026 | 80.72B |
| August 26, 2026 | 83.52B |
| August 25, 2026 | 83.26B |
| August 24, 2026 | 83.03B |
| August 21, 2026 | 82.92B |
| August 20, 2026 | 82.45B |
| August 19, 2026 | 83.05B |
| August 18, 2026 | 81.62B |
| August 17, 2026 | 80.76B |
| August 14, 2026 | 80.92B |
| August 13, 2026 | 82.61B |
| August 12, 2026 | 83.05B |
| August 11, 2026 | 83.05B |
| August 10, 2026 | 84.31B |
| August 07, 2026 | 84.92B |
| August 06, 2026 | 85.00B |
| August 05, 2026 | 85.74B |
| August 04, 2026 | 86.13B |
| August 03, 2026 | 83.70B |
| July 31, 2026 | 85.40B |
| July 30, 2026 | 85.49B |
| July 29, 2026 | 84.24B |
| July 28, 2026 | 84.79B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bayer AG | 87.98B |
| Dermapharm Holding SE | 3.471B |
| AstraZeneca PLC | 518.25B |
| GSK Plc | 113.72B |
| Johnson & Johnson | 641.85B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 574.38M |
| Revenue (Quarterly) | 6.318B |
| Total Expenses (Quarterly) | 5.748B |
| EPS Diluted (Quarterly) | 1.310 |
| Gross Profit Margin (Quarterly) | 58.26% |
| Profit Margin (Quarterly) | 9.09% |
| Earnings Yield | 3.90% |
| Operating Earnings Yield | 6.85% |
| Normalized Earnings Yield | 4.603 |